Dr. Nilofer S. Azad is Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She then completed a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland where she served as chief fellow. Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer. Her research efforts are dedicated to developing new drug combinations for patients with advanced cancer. In particular, Dr. Azad’s laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs. She is an active clinical trialist, leading multiple clinical trials of molecularly targeted agents for advanced cancer patients. Dr. Azad has received numerous grants for her work from entities such as the NCI (National Cancer Center), American Cancer Society, American Society of Clinical Research, Breakthrough Cancer Foundation, the Lustgarten Foundation, The Gateway Foundation, and the National Comprehensive Cancer Network, among others. She served as Principal for Johns Hopkins on the AACR Stand Up 2 Cancer Colorectal Cancer Dream Team and is a member of the Stand Up 2 Cancer Epigenetics Dream Team, leading the GI cancer initiatives for the group. Dr. Azad is a national leader in GI cancer, including serving as a member of the national NCI Colon Cancer Task Force and as Co-Chair of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. She has a presidential appointment to the National Cancer Advisory Board. Dr. Azad is rated as an Experienced provider by MediFind in the treatment of Niemann-Pick Disease. Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Colonoscopy.

Dr. Stephen J. Meltzer is a Professor of Medicine and Oncology at Johns Hopkins University, Division of Gastroenterology. He is the Director of GI Early Detection Biomarkers Laboratory and a member of the Johns Hopkins Kimmel Cancer Center. His research interests are Gastrointestinal cancer and precancer biomarker discover, development and validation; genomics, epigenomics and bioinformatics, early detection of cancer, outcomes research in cancer and precancer, risk stratification prediction in cancer and precancer, Barrett's esophagus, inflammatory bowel disease-associated cancer, liver cancer and gastric cancer. After receiving degree in Medicine at the State University of New York Medical School, Dr. Meltzer interned at Tulane University in New Orleans and University of Texas Medical Branch in Galveston, TX. He completed his fellowship training program in the University of Colorado and the Lenox Hill Hospital. He was an Assistant Professor in UCLA, Center for Health Science in 1987. Prior to joining the faculty at Johns Hopkins in 2006, he was Professor of Medicine and Pharmacology, Founder and Head of Aero digestive Cancer/Biomarker Program in School of Medicine, University of Maryland at Baltimore. He is an Associate Editor of Cancer Research and a member of the editorial board of Esophageal. He has published 152 original scientific papers in high-impact scientific journals. He also has 43 chapters, review articles, editorials, or letters to the editor; 1 book; and 139 abstracts to his name. He has given a plethora of invited lectures around the world, all involving his principal field of esophageal and gastrointestinal cancer research. He has been the recipient of numerous prestigious national and international awards, including the Robert and Sally D. Funderburg Award in Gastric Cancer Biology and membership in the American Society for Clinical Investigation. Special Interests: Gastrointestinal cancer and precancer biomarker discover, development and validation; genomics, epigenomics and bioinformatics, early detection of cancer, outcomes research in cancer and precancer, risk stratification prediction in cancer and precancer. Barrett's esophagus, inflammatory bowel disease-associated cancer, liver cancer, gastric cancer. Dr. Meltzer is rated as an Experienced provider by MediFind in the treatment of Niemann-Pick Disease. His top areas of expertise are Barrett Esophagus, Esophageal Cancer, Stomach Cancer, Colorectal Cancer, and Endoscopy.

Heather Riordan is a Pediatric Neurologist in Baltimore, Maryland. Dr. Riordan is rated as an Experienced provider by MediFind in the treatment of Niemann-Pick Disease. Her top areas of expertise are Cerebral Palsy, Focal Dystonia, Transient Tic Disorder, Spastic Diplegia Infantile Type, and Rhizotomy.

Ronald Cohn is a Pediatrics provider in Baltimore, Maryland. Dr. Cohn is rated as an Experienced provider by MediFind in the treatment of Niemann-Pick Disease. His top areas of expertise are Hypotonia, Muscle Atrophy, Infantile Neutropenia, and Micrognathia.

Bridget Pekrul is a Palliative Medicine provider in Baltimore, Maryland. Dr. Pekrul is rated as an Experienced provider by MediFind in the treatment of Niemann-Pick Disease. Her top areas of expertise are Niemann-Pick Disease and Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy.

Katharine Alter is a Physiatrist and a Pediatrics provider in Baltimore, Maryland. Dr. Alter is rated as an Experienced provider by MediFind in the treatment of Niemann-Pick Disease. Her top areas of expertise are Spasticity, Cerebral Palsy, Focal Dystonia, Drug Induced Dyskinesia, and Fasciotomy. Dr. Alter is currently accepting new patients.